New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Forbes Medi-Tech Secures Agreements

Forbes Medi-Tech Inc. (TSE:FMI and NASDAQ:FMTI) announced that it has secured sterols supply agreements for up to $40 million over a two-year period based on customer forecasts. This includes a major supply agreement between its manufacturing joint venture, Phyto-Source LP, and a large multinational company. The identity of the customer and contractual terms and conditions, for competitive reasons, will not be disclosed.

"This is a tremendous achievement for Forbes," said Charles Butt, President and CEO of Forbes Medi-Tech Inc. "We now have contracts for over 80% of our plant's capacity. These contracts are a true testament to our sterol manufacturing capabilities and the increasing demand for phytosterols in today's functional food and dietary supplement market."

Manufacturing of the phytosterols will be conducted by the Phyto-Source joint venture manufacturing facility in Pasadena, Texas, a 50-50 joint venture between Forbes and Chusei (USA) Inc. Forbes anticipates recognizing approximately 60 --70 % of the total revenue under these supply agreements on its income statement.

Approximately 800 tonnes of Phyto-Source's 1000 tonne annual production capacity has been secured by these new and existing contracts.

Under the new and existing contracts Forbes' revenue is scheduled to increase for at least three quarters commencing in the fourth quarter of 2002. Based on these contracts, the Company has increased its revenue projections for 2002 to $8 million. As the Company is continuing to negotiate additional sterols contracts, revenue guidance for 2003 will be announced in the fourth quarter of 2002.

Significant Increase in Men's Fertility Possible With 90-Day Pycnogenol(R) Treatment, Study Shows

CHICAGO, Sept. 20 /PRNewswire/ -- The antioxidant Pycnogenol(R) (pic-noj-en-all) improved the quality and function of sperm in men with fertility problems by a mean of 38% and 19%, respectively, after only 90 days of use, according to a new landmark clinical trial published today in the Journal of Reproductive Medicine, giving infertile couples new hope and a new alternative to more invasive procedures.

"Up to 60% of infertile couples have difficulty conceiving due to abnormalities in the male's sperm. By taking Pycnogenol(R) to increase normally functioning sperm naturally, couples may be able to (or potentially) avoid in-vitro fertilization and either enjoy improved natural fertility or undergo less invasive and less expensive fertility-promoting procedures," stated Dr. Scott Roseff, author of the study and Director of the West Essex Center for Advanced Reproductive Endocrinology (W.E. C.A.R.E.) in West Orange, NJ.

The seminal fluid surrounding the sperm is normally rich in antioxidants and protects the sperm from oxidative damage, according to Dr. Roseff, "but in sub-fertile men the seminal fluid, for unknown reasons, may not be protected by these antioxidants."

"We chose Pycnogenol(R) for the study because it is one of the richest natural sources of bioavailable and bioactive antioxidant compounds known. Pycnogenol(R) has been found to be many times more potent than other known antioxidants like vitamin C and vitamin E. The biological precursors of the oligomeric procyanidins such as catechin and taxifoline are effective and well-known free-radical scavengers," he said.

According to Dr. Roseff, the study clearly shows that taking daily doses of Pycnogenol(R) resulted in improved sperm quality and function because the natural antioxidant protection was supplemented.

Pycnogenol(R) is a natural plant extract originating from the bark of the Maritime pine that grows along the coast of southwest France. It represents a unique and natural combination of genetically programmed constant proportions of procyanidins, bioflavonoids and organic acids, making it a super antioxidant. Pycnogenol(R) is available today in hundreds of dietary supplements and multi-vitamin formulas worldwide.

The study was supported by Horphag Research, the original developers of Pycnogenol(R). For a complete copy of the study, contact The MWW Group at (312) 853-3131.

Natural Health Science, LLC, (NHS) based in New Jersey is the North American arm of Horphag Research, the original developers of Pycnogenol(R) (pic-noj-en-all) brand French maritime pine bark extract. Pycnogenol(R) is a registered trademark of Horphag Research Ltd., Guernsey, and its applications are protected by U.S. patents #4,698,360 / #5,720,956 and other international patents. NHS has the exclusive rights to market and sell Pycnogenol(R) and benefits from over thirty years of scientific research assuring the safety and efficacy of Pycnogenol(R) as a dietary supplement. For more information about Pycnogenol(R) visit the Horphag Research web site at http://www.pycnogenol.com/ .

CONTACT: Cheryl Costanzo of The MWW Group, +1-312-853-3131, ext. 228, [email protected]

Neptune Krill Oil(TM) (NKO(TM)) Scientifically proven to be significantly effective against premenstrual syndrome

MONTREAL, Sept. 18 /PRNewswire-FirstCall/ - The analysis of the interim data on this ongoing clinical study shows the benefits and the efficacy of Neptune Krill Oil(TM) (NKO(TM)) on patients diagnosed with premenstrual syndrome. Indeed, Neptune Krill Oil(TM) (NKO(TM)), a natural product composed of omega-3, potent phospholipids and antioxidants, works effectively on both the inflammation and pain as well as the emotional and psychological symptoms, by favourably affecting neurotransmitters within the brain.

Neptune Technologies & Bioressources inc. is conducting this Phase II clinical study in order to measure the effects of Neptune Krill Oil(TM) (NKO(TM)) on the symptoms of premenstrual syndrome. The study is performed according to current International Conference on Harmonisation guidelines on Good Clinical Practice. Data was collected and analysed from 46 of the 70 patients included in the study. This group of patients supplemented their diet with three grams of Neptune Krill Oil(TM) (NKO(TM)) per day and met with their doctor twice during an 8 week initial period. During their visits, the patients answered a scientifically validated self-assessment questionnaire relating to their symptoms during the week before menstruation.

JSS Medical Research Inc., the independent Contract Research Organization responsible for data analysis, reports: "The interim results on 64.3% of the 70 patients, which correspond to the 46 patients of the first group analysed, indicate that Neptune Krill Oil(TM) (NKO(TM)) significantly improves the overall emotional and physical symptoms of patients suffering from premenstrual syndrome". "Considering the study design and the power of our scientific results, the possibility that these results are not attributed to the beneficial effects of Neptune Krill Oil(TM) (NKO(TM)), but to chance alone, is one in a thousand. This explains why we feel very strongly that the final results on the total number of patients will be just as conclusive", says Dr. Tina Sampalis, Vice-President Research and Development at Neptune. "The interim results of this clinical study are encouraging and allow us to move a step closer towards the validation of the efficacy of our Neptune Krill Oil(TM) (NKO(TM)) on the improvement of certain human health conditions", she added.

Neptune Technologies & Bioressources inc. exploits marine biomasses with its extraction processes utilizing marine biomasses such as krill and other underexploited marine resources such as red crab and calanus. The company is industrializing its extraction process "Neptune OceanExtract(TM)" in order to offer its products to nutraceutical, cosmetic, cosmeceutical and biopharmaceutical markets.

Due to its technologies, Neptune Technologies & Bioressources Inc. is strategically well positioned in the huge and emerging markets based on the health and wellness concepts, markets in which natural biomass extraction will play an important role in developing nutrigenomics, the next wave in nutritional research.

Neptune Technologies & Bioressources Inc. is listed on the TSX Venture Exchange where its shares trade under the ticker symbol NTB, therefore this transaction is subject to its approval.

/CONTACT: Neptune Technologies & Bioressources Inc.: Dr. Tina Sampalis, [email protected];
Brigitte Beaulieu, [email protected]om;

Soy Isoflavones Are Safe Treatment for Menopause, Soy for Teenagers Reduces Cancer, New Studies Show

WASHINGTON, Sept. 19 /PRNewswire/ -- Two new scientific studies, one in Brazil and the other in California, have demonstrated anew the health benefits of soyfoods, with one study showing for the first time strong data indicating that isoflavone treatment can be a safe and effective alternative treatment for menopausal systems.

Isoflavones are naturally-occurring plant compounds found in soybeans that have become the subject of new and intensive study because they can help reduce the risk of disease.

The Brazilian study, conducted by scientists at the Federal University of Sao Paulo's School of Medicine, examined the change in both cardiovascular risk factors and in menopausal symptoms when a group of post-menopausal women aged 45 to 55 years received 100 milligrams of soy isoflavones daily.

"This study suggests that isoflavone l00 mg regime treatment may be a safe and effective alternative therapy for menopausal symptoms and may offer a benefit to the cardiovascular system," the study concluded. The study has been published in the journal Obstetrics and Gynecology, a publication of the American College of Obstetricians and Gynecologists.

The study demonstrated that the isoflavone treatment was effective in alleviating menopausal "hot flashes" and also lowered LDL (or "bad") cholesterol, suggesting a positive effect on the cardiovascular system.

The California study found that Asian-American women who ate soy during adolescence may reduce the risk of breast cancer in adulthood. The study was conducted at the University of Southern California's Keck School of Medicine and has been published in the journal Carcinogenesis.

The USC researchers found that American women of Chinese, Japanese and Filipino descent who consumed soyfoods on a regular basis during their teenage years had a much lower incidence of breast cancer later in life. It was theorized that the presence of isoflavones in the diet during the years that women develop breast tissue may provide a protective benefit.

Asian diets contain larger amounts of soyfoods than typical American diets, and researchers have long studied eating habits of those who consumed such soyfoods as soymilk, tofu, miso and soybeans and found that rates of breast cancer were lower in Asian women and that soy also helps prevent a number of other diseases and illnesses.

Zila Nutraceuticals' Ester-C Topical Concentrate to Be Used in Sea & Ski Product Line

PHOENIX--(BUSINESS WIRE)--Sept. 20, 2002--Zila Nutraceuticals (Inter-Cal Nutraceuticals), a division of Zila, Inc. (Nasdaq:ZILA), announced that Sea & Ski, a market leader in sun care products, launched a new core product line containing Ester-C(R) Topical Concentrate, an innovative form of natural vitamin C designed to last in emulsions and penetrate skin layers without chemicals.

The new Sea & Ski Platinum Sunscreen and Skin Care formula was developed for the needs of maturing skin and comes in both SPF 30 and SPF 50 protection.

"The Ester-C ingredient was the best option for Sea & Ski Platinum not only because of its powerful antioxidant qualities, but also because of its stable nature," said Arthur Vallejo, product development manager at Faulding Consumer, Inc., manufacturer of Sea & Ski Suncare. "We use such a high percentage of vitamin C that its regular form would oxidize and brown our product."

The Sea & Ski name has been a recognized brand name in sun care since the 1950s. For more information, visit www.sea-and-ski.com. F.H. Faulding & Co. Limited, manufacturer of drug, health and beauty aids, is Australia's oldest pharmaceutical company and has grown to a global company with offices and affiliations in more than 70 countries.

Zila, Inc., headquartered in Phoenix, Arizona, is an international provider of healthcare and biotechnology products for dental/medical professionals and consumers. Zila has three business units: Zila Pharmaceuticals, marketer of Zilactin(R) oral healthcare products, Peridex(R) prescription mouthrinse and ViziLite(R) oral examination kits, and manufacturer of patented swabs at Innovative Swab Technologies; Zila Nutraceuticals (Inter-Cal Nutraceuticals), manufacturer of patented Ester-C(R) branded products and Palmettx(R) Saw Palmetto; and, Zila BioTechnology, developer of OraTest(R) oral cancer detection products and Zila(R) Tolonium Chloride technologies for cancer and pre-cancer detection and treatment. For more information, visit www.zila.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31, 2001, and Form 10-Q for the quarter ended April 30, 2002, filed with the Securities and Exchange Commission.

--30--ATR/se*

The Nautilus Group Extends Agreement with Champion Nutrition; Nutritional Supplement Business Represents Strong Additional Sales Opportunity to Bowflex Customers

VANCOUVER, Wash.--(BUSINESS WIRE)--Sept. 19, 2002--The Nautilus Group, Inc. (NYSE:NLS), a leading marketer, developer, and manufacturer of branded health and fitness products, today announced the extension of its agreement with Champion Nutrition, a privately held manufacturer of nutritional supplements located in Concord, California. The Nautilus Group began selling Champion's nutritional supplements through its direct business segment in August of 2001.

"We are very pleased with our initial success in up-selling nutritional supplements to our customers through our direct sales channel," said Brian Cook, CEO of The Nautilus Group. "Nutritional supplement sales have proven to be a natural extension of our Bowflex and Nautilus product sales and we view this as a compelling long-term business opportunity."

Under the terms of the extended agreement, The Nautilus Group provided Champion with an interest-bearing loan of approximately $3 million and has an option to buy Champion for $6 million at any time before February 24, 2003.

About The Nautilus Group

The Nautilus Group, Inc. (formerly Direct Focus, Inc.) is a leading marketer, developer, and manufacturer of branded health and fitness products sold under such well-known names as Nautilus, Bowflex, Schwinn and StairMaster. The Company currently markets its Bowflex home fitness equipment and Nautilus Sleep Systems through its direct-marketing channel, using an effective combination of television commercials, infomercials, response mailings, the Internet, and inbound/outbound call centers. The Company sells its Nautilus, Schwinn and StairMaster commercial fitness equipment through its sales force and selected dealers to health clubs, government agencies, hotels, corporate fitness centers, colleges, universities, and assisted living facilities. The Nautilus Group also markets and sells a complete line of consumer fitness equipment, under its Nautilus, Schwinn and StairMaster brands, through a network of specialty dealers, distributors, and retailers worldwide. The Company is headquartered in Vancouver, Washington. The Nautilus Group is located on the Web at www.nautilusgroup.com.

From time to time, The Nautilus Group may issue forward-looking statements relating to its products and services, including statements regarding its Bowflex, Nautilus, Schwinn Fitness, and StairMaster businesses. Factors that could affect The Nautilus Group's actual results include its reliance on a limited product line, fluctuations in advertising rates, market acceptance of its existing and future products, growth management challenges including the growth resulting from the acquisition of the assets of Schwinn Fitness in September 2001 and StairMaster in February 2002, a decline in consumer spending due to unfavorable economic conditions, government regulatory action, its ability to effectively identify and negotiate any future strategic acquisitions, its ability to integrate the StairMaster business and any other acquired businesses into its operations, unpredictable events and circumstances relating to international operations including its use of foreign manufacturers, and general economic conditions. Please refer to our reports and filings with the Securities and Exchange Commission, including our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, for a further discussion of these risks and uncertainties. We also caution you not to place undue reliance on forward-looking statements, which speak only as of the date they are made. We undertake no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

Paxis Pharmaceuticals Launches Paclitaxel Operations Hauser, Inc. Founder to Lead Paxis Team

BOULDER, CO ‹ Paxis Pharmaceuticals announced today that its global operation for the production and sale of Paclitaxel, one of the world¹s leading chemotherapy drugs, has begun.

Paxis Pharmaceuticals, a pharmaceutical start-up company, acquired key manufacturing assets and licensed the rights to intellectual property from Hauser, Inc. (OTCBB:HAUS) in May of 2002. They assumed the lease on Hauser¹s Boulder, CO, Paclitaxel manufacturing facility and equipment that has the capacity to produce an excess of 200 kilograms of Paclitaxel per year.

³Our initial goal is to be the largest supplier of bulk Paclitaxel,² said Paxis Pharmaceuticals President Dr. Dean Stull, Ph.D. ³We have the capital, equipment, know-how, and key expert employees necessary to make Paxis a strong competitor in this growing segment of the pharmaceutical market.²

In a separate announcement, Dr. Dean Stull, Ph.D., founder of Hauser Inc., will serve as the Paxis team president as well as head up all technical and commercial efforts in the United States.

Vasili Patarkalishvili, Paxis Chairman and CEO, is also the CEO of NatEx, an affiliate of Paxis organized in the Republic of Georgia to supply Paxis with raw material for Paclitaxel production. Through this NatEx affiliate, Paxis acquired exclusive harvesting rights to a significant renewable resource of approximately 100,000 acres of Taxus baccata trees in the former soviet republic of Georgia. This unique partnership allows Paxis to work closely with the Georgian Agriculture and Forestry Ministries to minimize any impact on the forest. They utilize sustainable harvesting techniques in Georgia by only clipping a limited amount of new growth per tree. Based on initial forest surveys, Paxis has raw materials sufficient to manufacture up to 500 kilograms of Paclitaxel per year when running at full capacity.

Paclitaxel and related compounds (taxanes) are being evaluated in new cancer drugs, in cardiovascular stents, and for other health indications that should expand the market for Paclitaxel considerably. Paclitaxel annual sales are in excess of one billion dollars. It is estimated that the demand for Paclitaxel and related compounds could grow by 20 percent annually over the next 10 years.

Paxis Pharmaceuticals is a privately held Delaware corporation with cGMP manufacturing operations based in Boulder, Colorado. Their harvesting operations are based in the country of Georgia through their wholly owned NatEx affiliate. Paxis intends to manufacture and market the active pharmaceutical ingredient Paclitaxel and other related compounds found in the Taxus baccata tree. For more information on Paxis Pharmaceuticals visit http://www.paxispharma.com.

Contact:
Bill Keeney
Vice President and General Manager
Paxis Pharmaceuticals
(303) 448-9850
[email protected]

Reliv International Declares Stock Dividend

CHESTERFIELD, Mo., Sept. 19 /PRNewswire-FirstCall/ -- Reliv International, Inc. (Nasdaq: RELV), an international manufacturer and network marketer of nutritional supplements and other food technology products, today announced that the Board of Directors has declared a stock dividend of one share for each 5.25 issued and outstanding shares to all holders of record as of October 11, 2002. This stock dividend will represent approximately 19% of the issued and outstanding shares of Reliv.

Robert L. Montgomery, Chief Executive Officer of Reliv, stated that, "Our management and Board of Directors decided to declare a stock dividend in light of our now consistent profitability, our continued sales momentum and the resulting increases in both the market price of our stock and its liquidity. We want all of our shareholders to participate in and benefit from Reliv's success which is reflected in the market for our stock."

David Kreher, Chief Operating Officer and Chief Financial Officer for Reliv, said that, "Over the past nine months, the market price of Reliv's stock has risen from $1.25 per share (as of December 31, 2001) to over $4.00 per share presently and, in that time, average daily trading volume in the stock has increased from approximately 4,200 shares per day to over 35,000 shares per day.

"We expect our results for the third and fourth quarters of 2002 to continue to reflect the momentum and profitability levels we have achieved recently," he said. "We are continuing to experience growth in sales, sponsoring of new distributors and profitability compared to prior years results."

The stock dividend will be distributed to all shareholders of record of Reliv as of October 11, 2002. The actual distribution of the stock dividend will be effected within approximately 14 days after the record date. Fractional shares will not be issued. The Company will issue payment to shareholders for fractional shares based upon the closing price per share for the day preceding the record date.

Reliv International, Inc., based in suburban St. Louis, manufactures and distributes several lines of food products, including nutritional and fiber supplements, diet management products, functional foods and sports drink mixes. Its proprietary product lines include an extensive line of soy-based products. Reliv International's common stock trades on The Nasdaq Stock Market(R) under the symbol RELV.

NOTE: Any statement released by Reliv International, Inc. that is forward-looking is made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Editors and investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company's business prospect and performance. This includes economic, competitive, governmental, technological and other factors discussed in the Company's filings with the SEC on forms 10-K and 10-Q.

Green tea may fight allergies

Allergy sufferers may want to add green tea to their sniffle-fighting arsenal. New evidence suggests that drinking the popular brew may provide some relief. Researchers in Japan identified a compound in green tea that, in laboratory tests, blocks a key cell receptor involved in producing an allergic response. The compound, methylated epigallocatechin gallate (EGCG), may have a similar effect in humans, they say. Their study will be described in the Oct. 9 print issue of the Journal of Agricultural and Food Chemistry, a peer-reviewed publication of the American Chemical Society, the world's largest scientific society.

Although similar compounds in green tea have previously been shown to be anti-allergenic, this particular compound appears to be the most potent, the researchers say.

"Green tea appears to be a promising source for effective anti-allergenic agents," says Hirofumi Tachibana, the study's chief investigator and an associate professor of chemistry at Kyushu University in Fukuoka, Japan. "If you have allergies, you should consider drinking it."

For years, people have been drinking tea to fight the sneezing, coughing and watery eyes that are characteristic of colds and allergies. The new study adds to a small but growing body of scientific evidence from both cell and animal studies that it may actually work, particularly green tea.

No one has proven, however, that anti-allergenic compounds found thus far have an actual therapeutic effect in humans who ingest green tea. If it works, the brew may be useful against a wide range of allergens, including pollen, dust, pet dander and certain chemicals, Tachibana says. Further studies are needed.

EGCG is one of the most abundant and biologically active antioxidants found in tea. It is believed to be responsible for tea's beneficial health effects. The compound is found in higher concentrations in green tea, the least processed of teas, than in black and oolong varieties.

Previous studies have shown that EGCG fights allergic reactions in rodents that were given the compound orally, but researchers are just beginning to understand how it might work.

It now appears that the compound works by blocking the production of histamine and immunoglobulin E (IgE), two compounds in the body that are chiefly involved in triggering and sustaining allergic reactions, Tachibana says.

The current study shows, for the first time, that a methylated form of EGCG can block the IgE receptor, which is a key receptor involved in an allergic response. The effect was demonstrated using human basophils, which are blood cells that release histamine.

Methylated EGCG appears to elicit a stronger anti-allergenic response than normal EGCG, making it the strongest anti-allergen compound found in tea, the researchers say.

Although promising against allergies, no one knows how much green tea is needed to have a therapeutic effect, or which green tea varieties work best, the researchers add. They are currently looking for additional anti-allergenic compounds in the tea.

Green tea has been called the second-most consumed beverage in the world, behind water. It is very popular in Japan, and has a growing following in the United States, where black tea is favored. Tachibana's study adds to an expanding list of the potential health benefits offered by green tea. In addition to allergies, it is reported to fight cancer, cardiovascular disease, arthritis and tooth decay.

Approximately 50 million people in this country suffer from some type of allergy. Until studies are done to determine whether green tea is actually beneficial to humans with allergies, experts urge consumers to see their doctor for the best advise on treatment options. Among those options: minimizing or avoiding suspected allergens (i.e. dust, pollen, certain foods). Exercise and proper diets are also thought to alleviate the effect of allergies.

Funding for this study was provided in part by grants from the Program for Promotion of Basic Research Activities for Innovative Biosciences (PROBRAIN).

Dr. Tachibana's associates in this study were Yoshinori Fujimura and Koji Yamada of Kyushi University, Mari Maeda-Yamamoto of the National Research Institute of Vegetables and Tea Sciences, and Toshio Miyase and Mitsuaki Sano of the University of Shizuoka.

###

— Mark T. Sampson

The online version of the research paper cited above was initially published Aug. 30 on the journal's Web site. Journalists can arrange access to this site by sending an e-mail to [email protected] or calling the contact person for this release.

Hirofumi Tachibana, Ph.D., is an associate professor of chemistry in the department of bioscience and biotechnology at Kyushu University in Fukuoka, Japan.

New Soy Smoothie Smoothes Its Way Into New York; Now Available at Gristede's Stores: Frulatte Combines Great Taste And Natural Ingredients

9/17/2002 OAKLAND, Calif., Sep 17, 2002 /PRNewswire via COMTEX/ -- Frulatte Foods Co. announced today that its new FRULATTE Energizing Smoothies, a unique combination of great taste, nutrition and convenience, is now available at Gristede's. Designed for health-conscious people with active lifestyles, FRULATTE Smoothies are a fresh, natural and satisfying blended beverage that supplies sustained energy and key nutrients.

"The smoothie industry has undergone tremendous growth, and FRULATTE Smoothies continue to appeal to consumers as they look for a light meal smoothie that gives them the energy and health benefits they want, yet doesn't sacrifice taste or convenience," said Amy Cadora, Vice President and General Manager of Frulatte Foods Co. "This is especially true of New Yorkers who are constantly on the go and have been demanding a product that meets their needs and fits their lifestyle."

Perfect in place of a light meal, anytime anywhere, FRULATTE Smoothies can also be used by health conscious people looking to control calories and manage their weight. Inspired by the Italian word "frullato" which means cold, creamy shakes, FRULATTE Smoothies are available in six delicious flavors -- Milk Chocolate, Strawberry-Kiwi, Orange-Mango, Mocha Cappuccino, Cranberry-Raspberry and Lemon Creme.

Each FRULATTE Smoothie is an energizing, fat free or low fat MEAL-IN-MOTION(TM), which contains:

  • The protein equal to two eggs (10 grams, including 5 grams from non-genetically modified Solae(TM) brand soy protein)
  • The calcium of 11/2 cups of milk (50% of the recommended daily requirement)
  • 1-1/2 servings of fruit (fruit flavors only)
  • 90-100% real fruit juice (fruit flavors only)
  • Fiber, Folic Acid, Vitamins C, D and E and other minerals
  • 15% of the Daily Value for Zinc and Selenium (two key antioxidant minerals)
  • Lactose-free (except for Mocha Cappuccino)
  • Only 220-250 calories
  • No fat or low fat
  • No preservatives
  • No artificial flavors

FRULATTE Energizing Smoothies are available in the refrigerated section of the grocery store. Each 10.5 fl. oz. bottle sells for a suggested retail price of $2.49. For more information please visit www.frulatte.com. Frulatte is currently available in Gristede's, Safeway, 7-Eleven, Ralphs, Raley's, Vons, Pavilions, Nob Hill Foods, Bel Air Markets, Carrs, Dominick's, Randalls, Tom Thumb, Genuardis, and Harry and David retail stores.

About Frulatte Foods Co.
Oakland, CA-based, Frulatte Foods Co. is a division of INOBYS Ltd., which is a new consumer products subsidiary of Yamanouchi Consumer Inc., the US-based consumer products subsidiary of Yamanouchi Pharmaceuticals. Yamanouchi is Japan's second largest pharmaceutical company, with worldwide consolidated operations contributing over $4 billion in sales revenue for the year 2000.

NOTE: Solae(TM) is a trademark of Protein Technologies International, Inc. -- a DuPont Business.